NASDAQ:INCY Incyte - INCY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. $71.04 -0.10 (-0.14%) (As of 03/30/2023 04:33 PM ET) Add Compare Share Share Today's Range$70.84▼$71.4850-Day Range$70.23▼$86.0152-Week Range$65.07▼$86.29Volume912,560 shsAverage Volume1.69 million shsMarket Capitalization$15.84 billionP/E Ratio46.74Dividend YieldN/APrice Target$85.64 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Incyte MarketRank™ ForecastAnalyst RatingHold2.36 Rating ScoreUpside/Downside20.6% Upside$85.64 Price TargetShort InterestBearish2.93% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.47Based on 13 Articles This WeekInsider TradingSelling Shares$7.95 M Sold Last QuarterProj. Earnings Growth37.99%From $3.29 to $4.54 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.82 out of 5 starsMedical Sector56th out of 1,009 stocksCommercial Physical Research Industry4th out of 16 stocks 3.2 Analyst's Opinion Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 6 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $85.64, Incyte has a forecasted upside of 20.6% from its current price of $71.04.Amount of Analyst CoverageIncyte has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.93% of the outstanding shares of Incyte have been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 4.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIncyte has received a 71.02% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Pharmacovigilance services", and "Clinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Incyte is -1.23. Previous Next 2.5 News and Social Media Coverage News SentimentIncyte has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Incyte this week, compared to 6 articles on an average week.Search Interest16 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,947,106.00 in company stock.Percentage Held by Insiders17.50% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Incyte are expected to grow by 37.99% in the coming year, from $3.29 to $4.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 46.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 46.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.24.Price to Earnings Growth RatioIncyte has a PEG Ratio of 3.07. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Incyte (NASDAQ:INCY) StockIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE.Read More Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Stock News HeadlinesMarch 29, 2023 | finance.yahoo.comBiotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces SetbackMarch 27, 2023 | finance.yahoo.comCompany News for Mar 27, 2023March 30, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 27, 2023 | businesswire.comIncyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)March 25, 2023 | americanbankingnews.comIncyte (NASDAQ:INCY) Lifted to "Market Perform" at SVB SecuritiesMarch 24, 2023 | finance.yahoo.comIncyte Stock Dives On A Surprise Rejection For Its Biggest MoneymakerMarch 24, 2023 | benzinga.comSecond Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'March 23, 2023 | finance.yahoo.comIncyte (INCY) Receives FDA Approval for Skin Cancer TreatmentMarch 30, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 22, 2023 | finance.yahoo.comIncyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)March 22, 2023 | americanbankingnews.comWilliam Blair Reiterates Outperform Rating for Incyte (NASDAQ:INCY)March 20, 2023 | finance.yahoo.comIncyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase IIMarch 18, 2023 | businesswire.comIncyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental VitiligoMarch 18, 2023 | businesswire.comIncyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in VitiligoMarch 9, 2023 | finance.yahoo.comIncyte (INCY) Down 8.3% Since Last Earnings Report: Can It Rebound?March 7, 2023 | finance.yahoo.comDeclining Stock and Decent Financials: Is The Market Wrong About Incyte Corporation (NASDAQ:INCY)?March 3, 2023 | finance.yahoo.comIncyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with MyelofibrosisMarch 3, 2023 | finance.yahoo.comIncyte to discontinue late-stage trial for bone marrow cancer drug combinationFebruary 24, 2023 | finance.yahoo.comIncyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and AdolescentsFebruary 14, 2023 | finance.yahoo.comSyndax (SNDX) to Report Q4 Earnings: What's in the Cards?February 13, 2023 | finance.yahoo.comInsider traders use ETFs to front-run M&A deals, academics sayFebruary 11, 2023 | seekingalpha.comIncyte skin disorder drug shows durable efficacy in 1 year data from mid-stage trialFebruary 9, 2023 | finance.yahoo.comIncyte Corporation (NASDAQ:INCY) Q4 2022 Earnings Call TranscriptFebruary 7, 2023 | finance.yahoo.comMarkets Rise on Powell's Inflation CommentsFebruary 7, 2023 | benzinga.comIncyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says AnalystFebruary 7, 2023 | finance.yahoo.comIncyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical ProgramsFebruary 3, 2023 | 247wallst.comPiper Sandler Initiates Coverage of Incyte with Overweight RecommendationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Company Calendar Last Earnings2/07/2023Today3/30/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INCY CUSIP45337C10 CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,324Year Founded1991Price Target and Rating Average Stock Price Forecast$85.64 High Stock Price Forecast$113.00 Low Stock Price Forecast$61.00 Forecasted Upside/Downside+20.4%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$1.52 Trailing P/E Ratio46.80 Forward P/E Ratio21.62 P/E Growth3.05Net Income$340.66 million Net Margins10.03% Pretax Margin15.59% Return on Equity11.45% Return on Assets8.72% Debt Debt-to-Equity Ratio0.01 Current Ratio3.54 Quick Ratio3.50 Sales & Book Value Annual Sales$3.39 billion Price / Sales4.67 Cash Flow$2.47 per share Price / Cash Flow28.84 Book Value$19.64 per share Price / Book3.62Miscellaneous Outstanding Shares222,965,000Free Float183,946,000Market Cap$15.86 billion OptionableOptionable Beta0.74 Social Links Key ExecutivesHerve HoppenotChairman, President & Chief Executive OfficerChristiana StamoulisChief Financial Officer & Executive Vice PresidentSteven H. SteinChief Medical Officer & Executive Vice PresidentDashyant DhanakChief Scientific Officer & Executive VPBarry FlannellyEVP & General Manager-North AmericaKey CompetitorsICON PublicNASDAQ:ICLRCharles River Laboratories InternationalNYSE:CRLMedpaceNASDAQ:MEDPMolina HealthcareNYSE:MOHQuest DiagnosticsNYSE:DGXView All CompetitorsInsiders & InstitutionsNeo Ivy Capital ManagementBought 1,610 shares on 3/27/2023Ownership: 0.001%Victory Capital Management Inc.Sold 115,303 shares on 3/10/2023Ownership: 0.075%Rockefeller Capital Management L.P.Bought 11,207 shares on 3/6/2023Ownership: 0.012%Voya Investment Management LLCBought 2,580 shares on 2/28/2023Ownership: 0.068%NatixisSold 140,292 shares on 2/24/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions INCY Stock - Frequently Asked Questions Should I buy or sell Incyte stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares. View INCY analyst ratings or view top-rated stocks. What is Incyte's stock price forecast for 2023? 14 brokerages have issued 1-year target prices for Incyte's stock. Their INCY share price forecasts range from $61.00 to $113.00. On average, they expect the company's stock price to reach $85.64 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price. View analysts price targets for INCY or view top-rated stocks among Wall Street analysts. How have INCY shares performed in 2023? Incyte's stock was trading at $80.32 at the start of the year. Since then, INCY stock has decreased by 11.4% and is now trading at $71.14. View the best growth stocks for 2023 here. When is Incyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our INCY earnings forecast. How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, February, 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.03. The biopharmaceutical company had revenue of $926.70 million for the quarter, compared to the consensus estimate of $880.25 million. Incyte had a trailing twelve-month return on equity of 11.45% and a net margin of 10.03%. The business's quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.07) EPS. Read the conference call transcript. What ETFs hold Incyte's stock? ETFs with the largest weight of Incyte (NASDAQ:INCY) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Hennessy Stance ESG Large Cap ETF (STNC), ARK Genomic Revolution ETF (ARKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), WBI BullBear Quality 3000 ETF (WBIL), VanEck Biotech ETF (BBH), WisdomTree U.S. Growth & Momentum Fund (WGRO) and IQ U.S. Mid Cap R&D Leaders ETF (MRND). What is Hervé Hoppenot's approval rating as Incyte's CEO? 22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA). What is Incyte's stock symbol? Incyte trades on the NASDAQ under the ticker symbol "INCY." Who are Incyte's major shareholders? Incyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.05%), Geode Capital Management LLC (1.74%), First Trust Advisors LP (1.52%), Price T Rowe Associates Inc. MD (0.86%), Morgan Stanley (0.85%) and Norges Bank (0.70%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Incyte's stock price today? One share of INCY stock can currently be purchased for approximately $71.14. How much money does Incyte make? Incyte (NASDAQ:INCY) has a market capitalization of $15.86 billion and generates $3.39 billion in revenue each year. The biopharmaceutical company earns $340.66 million in net income (profit) each year or $1.52 on an earnings per share basis. How many employees does Incyte have? The company employs 2,324 workers across the globe. How can I contact Incyte? Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750. This page (NASDAQ:INCY) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.